6.
Schaerlaekens S, Jacobs L, Stobbelaar K, Cos P, Delputte P
. All Eyes on the Prefusion-Stabilized F Construct, but Are We Missing the Potential of Alternative Targets for Respiratory Syncytial Virus Vaccine Design?. Vaccines (Basel). 2024; 12(1).
PMC: 10819635.
DOI: 10.3390/vaccines12010097.
View
7.
McLellan J, Chen M, Leung S, Graepel K, Du X, Yang Y
. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013; 340(6136):1113-7.
PMC: 4459498.
DOI: 10.1126/science.1234914.
View
8.
Rezende W, Neal H, Dutch R, Piedra P
. The RSV F p27 peptide: current knowledge, important questions. Front Microbiol. 2023; 14:1219846.
PMC: 10320223.
DOI: 10.3389/fmicb.2023.1219846.
View
9.
Vigerust D, Shepherd V
. Virus glycosylation: role in virulence and immune interactions. Trends Microbiol. 2007; 15(5):211-8.
PMC: 7127133.
DOI: 10.1016/j.tim.2007.03.003.
View
10.
Adhikari B, Hassan F, Harrison C, Bard J, Dunn J, Kehl S
. A multi-center study to determine genetic variations in the fusion gene of respiratory syncytial virus (RSV) from children <2 years of age in the U.S. J Clin Virol. 2022; 154:105223.
DOI: 10.1016/j.jcv.2022.105223.
View
11.
Foley D, Phuong L, Englund J
. Respiratory syncytial virus immunisation overview. J Paediatr Child Health. 2020; 56(12):1865-1867.
DOI: 10.1111/jpc.15232.
View
12.
Re S, Mizuguchi K
. Glycan Cluster Shielding and Antibody Epitopes on Lassa Virus Envelop Protein. J Phys Chem B. 2021; 125(8):2089-2097.
DOI: 10.1021/acs.jpcb.0c11516.
View
13.
Blunck B, Aideyan L, Ye X, Avadhanula V, Ferlic-Stark L, Zechiedrich L
. Antibody responses of healthy adults to the p27 peptide of respiratory syncytial virus fusion protein. Vaccine. 2021; 40(3):536-543.
PMC: 8755595.
DOI: 10.1016/j.vaccine.2021.11.087.
View
14.
Verwey C, Madhi S
. Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus. BioDrugs. 2023; 37(3):295-309.
PMC: 10127166.
DOI: 10.1007/s40259-023-00596-4.
View
15.
Li Y, Wang X, Blau D, Caballero M, Feikin D, Gill C
. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022; 399(10340):2047-2064.
PMC: 7613574.
DOI: 10.1016/S0140-6736(22)00478-0.
View
16.
Johnson S, Oliver C, Prince G, Hemming V, Pfarr D, Wang S
. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997; 176(5):1215-24.
DOI: 10.1086/514115.
View
17.
Britton A, Roper L, Kotton C, Hutton D, Fleming-Dutra K, Godfrey M
. Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024; 73(32):696-702.
DOI: 10.15585/mmwr.mm7332e1.
View
18.
Tan L, Coenjaerts F, Houspie L, Viveen M, van Bleek G, Wiertz E
. The comparative genomics of human respiratory syncytial virus subgroups A and B: genetic variability and molecular evolutionary dynamics. J Virol. 2013; 87(14):8213-26.
PMC: 3700225.
DOI: 10.1128/JVI.03278-12.
View
19.
Fuentes S, Coyle E, Beeler J, Golding H, Khurana S
. Antigenic Fingerprinting following Primary RSV Infection in Young Children Identifies Novel Antigenic Sites and Reveals Unlinked Evolution of Human Antibody Repertoires to Fusion and Attachment Glycoproteins. PLoS Pathog. 2016; 12(4):e1005554.
PMC: 4839671.
DOI: 10.1371/journal.ppat.1005554.
View
20.
Watanabe Y, Bowden T, Wilson I, Crispin M
. Exploitation of glycosylation in enveloped virus pathobiology. Biochim Biophys Acta Gen Subj. 2019; 1863(10):1480-1497.
PMC: 6686077.
DOI: 10.1016/j.bbagen.2019.05.012.
View